HOME >> MEDICINE >> NEWS
Trial opens new possibilities for improving survival with a novel heart attack drug

CHICAGO -- While the results of a new trial showed that a novel drug intended to reduce the extent of cell death after heart attack did not do so, the surprising finding that it reduced the death rate in patients who received angioplasties opens an intriguing new line of investigation, according to Duke University Medical Center researchers.

The drug, known as pexelizumab, was tested in a Phase II trial in conjunction with either clot-busting medications or angioplasty in acute heart attack patients to reduce the amount of tissue death, or infarct size, following treatment. The researchers, led by Duke cardiologists Christopher Granger, M.D., and Kenneth Mahaffey, M.D., found that while the infarct size remained the same in the treated and untreated groups, there was a greater than three times reduction (1.8 percent vs. 5.9 percent) in the death rate after 90 days in the patients who received the drug in conjunction with angioplasty.

"Unexpected findings like these can in many ways be the most exciting, because they open up whole new avenues of investigation," Granger said. He presented the results of the trial (Nov. 18, 2002) at the 75th annual scientific session of the American Heart Association.

"Although pexelizumab did not reduce the size of infarcts, the results may be pointing toward a novel mechanism that seems to benefit some patients with acute heart attacks," Granger continued. "This is quite exciting and worthy of further study."

In many ways, heart attack patients suffer twice. First, when blood flow is cut off to heart muscle during the attack, the resulting lack of oxygen kills or damages heart muscle cells. Then, after blood flow is restored, either by medication or angioplasty, the starved muscle cells are damaged again as a result of the sudden return of oxygen-rich blood, a condition known as reperfusion injury.

To date, no effective therapy has been discovered to reduce or stop the damage of reperfusion in
'"/>

Contact: Richard Merritt
merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
18-Nov-2002


Page: 1 2 3

Related medicine news :

1. Trial reveals safer and simpler approach to treating children with cystic fibrosis
2. Trials launched to test treatment of cognitive dysfunction in schizophrenia
3. Randomisation phase of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) completed
4. Trials on hormone therapy and hypertension treatment change practice, medication usage of patients
5. Trial results have dramatically reduced HRT use
6. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
7. Clinical Trials Litigation: Legal & Ethical Issues in Human Subjects Research
8. National Lung Screening Trial
9. New awards, expanded focus for Pediatric AIDS Clinical Trials Group
10. AAPS Workshop to Examine Chemistry and Manufacturing Controls Trials, Emerging Products
11. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/15/2019)... ... ... Nashville Fertility Center (NFC) is proud to announce that Kristin Van Heertum ... to treating general infertility, Dr. Van Heertum offers expertise in fertility surgery and treatment ... Van Heertum joining the practice and believes she is the perfect fit. According to ...
(Date:10/11/2019)... , ... October 11, 2019 , ... A Topping Out ... new headquarters facility by general contractors Adolfson & Peterson Construction. The event celebrated reaching ... at 8190 Midtown Road in Dallas. The first of its kind in Texas, STA’s ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... Caring.com, a ... Report on the Best and Worst Places for Seniors to Live. All 50 states ... engagement, transportation, quality of life and workforce development. , According to the ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... CA (PRWEB) , ... October 08, 2019 , ... Dr. ... gum disease in San Jose, CA experience relief from this common and treatable condition. ... in order to save adults from living with uncomfortable symptoms, including tender and bleeding ...
Breaking Medicine News(10 mins):
(Date:10/8/2019)... ... October 08, 2019 , ... ... farmers a wider range of novel, microbial-based crop protection products. , Under the ... natural product starting points. In a first for the agriculture industry, Corteva will ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... today announced that FocalPoint Holdings, a privately-held investment and management firm specializing ... more than 8,000 ophthalmology and optometry providers Luma Health’s patient relationship technology ...
(Date:10/8/2019)... ... October 08, 2019 , ... AdventHealth Wesley ... and provide safer, convenient options for patients who require treatment. The hospital is ... enhanced mammography is used to detect tumors in dense breasts that may not ...
Breaking Medicine Technology:
Cached News: